Rein reports early Phase II data for inhaled IPF drug
Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03,…
Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03,…
Beeline Medicines has unveiled detailed data behind its Bristol Myers Squibb (BMS)- licenced drug afimetoran, which showed it provided statistically…
Eli Lilly and Company has reported promising 52-week results from the Phase IIIb TOGETHER-PsA trial assessing Taltz (ixekizumab) alongside Zepbound…
Amgen’s Phase III Sjögren's disease trial has met its primary endpoint, marking the latest sign that the indication could be…
California-based biopharma company Alumis is taking its immunology candidate, envudeucitinib, to Phase III in a type of lupus, despite the…
Amgen and AstraZeneca’s co-developed blockbuster therapy Tezspire (tezepelumab) scored a Phase III win in a third epithelial-driven inflammatory disease –…
Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The…
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during a Phase…
As Spring edges closer, rheumatology experts are preparing for The European Lupus Society’s 15th Annual European Lupus Meeting, which will…
On 29 September 2025, at the European Respiratory Society (ERS) Conference held in Amsterdam, the Netherlands, Vicore Pharma presented results…